Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · IEX Real-Time Price · USD
13.98
+0.73 (5.51%)
At close: May 3, 2024, 4:00 PM
14.31
+0.33 (2.36%)
After-hours: May 3, 2024, 7:40 PM EDT
Pliant Therapeutics Revenue
In the year 2023, Pliant Therapeutics had annual revenue of $1.58M, a decrease of -83.69%.
Revenue (ttm)
$1.58M
Revenue Growth
-83.69%
P/S Ratio
533.71
Revenue / Employee
$10,000
Employees
158
Market Cap
843.26M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.58M | -8.11M | -83.69% |
Dec 31, 2022 | 9.69M | 2.11M | 27.91% |
Dec 31, 2021 | 7.57M | -34.25M | -81.89% |
Dec 31, 2020 | 41.82M | -15.24M | -26.70% |
Dec 31, 2019 | 57.05M | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 1.99B |
Healthcare Services Group | 1.68B |
Paragon 28 | 216.39M |
Evolus | 202.09M |
Cytek Biosciences | 193.02M |
OrthoPediatrics | 148.73M |
Sage Therapeutics | 91.06M |
REGENXBIO | 90.24M |
PLRX News
- 3 days ago - Pliant Therapeutics to Participate in Upcoming Investor Events - GlobeNewsWire
- 5 weeks ago - Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference - GlobeNewsWire
- 7 weeks ago - Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results - GlobeNewsWire
- 2 months ago - Pliant Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis - GlobeNewsWire
- 4 months ago - Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis - GlobeNewsWire